Overview Recent research demonstrates a critical insight that should reshape how individuals and organisations approach artificial intelligence: the timing, context, and intentionality behind AI use fundamentally determine whether these tools …
Indirect Treatment Comparisons in France: Why HAS Exposes the Limits of Multi-Market Evidence Strategies For over a decade, market access teams have observed a persistent pattern: indirect treatment comparisons (ITCs) …
A Structural Shift in Evidence Generation for Medicines and Medical Technologies The implementation of the EU Health Technology Assessment Regulation (HTAR, 2021/2282) marks a fundamental transition in how clinical and …
What It Is, How It Works, and What Success Actually Requires Introduction: The Hidden Architecture of French Reimbursement In France, a single institution holds the power to determine whether a …